Company Overview

NeoChord, Inc.

Founded in 2007 and based in St. Louis Park, Minnesota, NeoChord, Inc. is a privately held medical technology company leading the advancement of minimally invasive repair for degenerative mitral regurgitation (DMR).

NeoChord’s DS1000 system received CE market clearance in December 2012. NeoChord received IDE approval from the FDA for the US pivotal trial, the ReChord Trial, in May 2016.